ReviewEco-Environment & Health2022
Next generation per- and poly-fluoroalkyl substances: Status and trends, aquatic toxicity, and risk assessment.
Review in Eco-Environment & Health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 131 citations in OpenAlex.
- Review
- Molecular insights into the selective separation of perfluoroalkyl substances: The construction and application of capsule adsorbents.Eco-Environment & Health · 2026Article
- Review
- Understanding and Reporting PFAS Exposure: Wide-Scope Retrospective Suspect Screening of High-Resolution Mass Spectrometry Data from Exposomics Studies.Environmental science & technology · 2026Article
- Incomplete versus Sustained Innate-Immune Responses in the Medicinal Leech following Chronic, Environmentally Relevant Per- and Polyfluoroalkyl Substance Exposure.Environment & health (Washington, D.C.) · 2026Article
- Development of a QSAR model for predicting PPARα activation by PFAS based on human in vitro data of a comprehensive panel of legacy and novel PFAS.Archives of toxicology · 2026Article
- PFAS and One Health: integrating human, animal, and environmental perspectives.Archives of toxicology · 2026Review
- Presence of Legacy and Emerging PFAS in Human Liver Specimens Banked in the United States from 2000 to 2024.Environmental science & technology · 2026Article
- Review
- From carboxylates to chlorinated sulfonates: Contrasting fate and treatment prospects of GenX and F53B in WWTPs.The Science of the total environment · 2025Review
- Synergistic toxicity in alcohol-associated liver disease and PFAS exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2025Review
- High-Throughput Small-Scale Platform for Synthesis, Characterization, and Modeling of Per- and Polyfluoroalkyl Substances Analogs.Environmental science & technology letters · 2025Article
- Characterization of Per- and Polyfluoroalkyl Substances in Drinking Water Sources in the Greater Montreal Area, Quebec, Canada.ACS ES&T water · 2025Article
- Molecular and Computational Studies Reveal That Per- and Polyfluoroalkyl Substances Can Impair Protamine-DNA Interaction, Potentially Inducing DNA Damage.Biomolecules · 2025Article
- Perfluoroalkyl substances: a risk for the aquatifc environment? A 1-year case study in river waters of central Italy.Environmental science and pollution research international · 2025Article
- Hepatotoxicity in Carp (Animals : an open access journal from MDPI · 2025Article
- Per- and polyfluoroalkyl substances in untreated and treated sludge/biosolids from 27 water resource recovery facilities across the United States and Canada.Water environment research : a research publication of the Water Environment Federation · 2025Article
- Enzymatic Degradation of PFAS: Current Status and Ongoing Challenges.ChemSusChem · 2025Review
- Considerations for Measurements of Aggregate PFAS Exposure in Precision Environmental Health.ACS measurement science au · 2024Review
- Speciation and biogeochemical behavior of perfluoroalkyl acids in soils and their environmental implications: A review.Eco-Environment & Health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Widespread application of poly- and per-fluoroalkyl substances (PFAS) has resulted in some substances being ubiquitous in environmental matrices. That and their resistance to degradation have allowed them to accumulate in wildlife and humans with potential for toxic effects. While specific substances of concern have been phased-out or banned, other PFAS that are emerging as alternative substances are still produced and are being released into the environment. This review focuses on describing three emerging, replacement PFAS: perfluoroethylcyclohexane sulphonate (PFECHS), 6:2 chlorinated polyfluoroalkyl ether sulfonate (6:2 Cl-PFAES), and hexafluoropropylene oxide dimer acid (HFPO-DA). By summarizing their physicochemical properties, environmental fate and transport, and toxic potencies in comparison to other PFAS compounds, this review offers insight into the viabilities of these chemicals as replacement substances. Using the chemical scoring and ranking assessment model, the relative hazards, uncertainties, and data gaps for each chemical were quantified and related to perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) based on their chemical and uncertainty scores. The substances were ranked PFOS > 6:2 Cl-PFAES > PFOA > HFPO-DA > PFECHS according to their potential toxicity and PFECHS > HFPO-DA > 6:2 Cl-PFAES > PFOS > PFOA according to their need for future research. Since future uses of PFAS remain uncertain in the face of governmental regulations and production bans, replacement PFAS will continue to emerge on the world market and in the environment, raising concerns about their general lack of information on mechanisms and toxic potencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.